When lyophilizing a challenging biologic drug product, use an integrated approach optimizing formulation and process parameters together.
- DEA Reveals Hidden Costs Of Analytical Validation Guidelines
- Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
- FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
- You Can't CAPA What You Can't Classify
- 6 Modeling Approaches That Make Complex Bioprocess Data Useful
- Building Trust In AI For Computerized System Validation
- A Gentler Cell Line Selection Method Using microRNA
GUEST COLUMNISTS
-
DEA Reveals Hidden Costs Of Analytical Validation Guidelines
By treating distinct validation guidelines as decision-making units, data envelopment analysis (DEA) allows for the mathematical evaluation of their resource efficiency.
-
Qualification And Validation Of Depyrogenation Tunnels And Autoclaves
Systemic vulnerabilities exist in thermal uniformity assurance, steam penetration verification, regulatory fragmentation, and tech harmonization.
-
FDA Modernizes Container Closure Guidance: What Is Changing And Why It Matters
The proposed revision reflects changes in packaging technology, drug delivery systems, quality risk management, and more that have occurred since 1999's guidance.
-
You Can't CAPA What You Can't Classify
An LLM or agentic error can occur with no component broken in any way the QMS recognizes. Classifying it takes two fields: the error type and the error origination point.
-
6 Modeling Approaches That Make Complex Bioprocess Data Useful
AI algorithms can reduce data dimensionality more faithfully by interpreting multivariate features relevant to prediction or control.
-
Building Trust In AI For Computerized System Validation
Using AI for CSV might feel like the students are grading their own papers. One consultant explains why it's not the same, namely, there are no subjective judgment calls.
-
A Gentler Cell Line Selection Method Using microRNA
Traditional selection stresses surviving cells. New research shows how structurally interacting RNA may use endogenous microRNA for a faster, nontoxic selection process.
BIOSIMILAR WHITE PAPERS
-
Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies
Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.
-
A Shift Towards Biofluorescent Particle Counters In Manufacturing5/12/2025
Sterility in injectable drug manufacturing is vital for patient safety and efficiency. Discover how biofluorescent particle counters revolutionize contamination control, regulatory compliance, and operational excellence in modern pharma.
-
Why Choose Robotic Processing For Small Batch Aseptic Filling1/9/2026
Reducing human intervention in aseptic filling is critical for safety and cost efficiency. Learn why automation is essential for small-batch applications and how it’s transforming sterile drug manufacturing.
-
Aseptic Process Design And Simulation Under Annex 1 Guidelines1/9/2026
Gain insight into how Annex 1 reshapes aseptic process validation, as well as into risk reduction by design and why isolators are redefining modern sterile manufacturing standards.
-
ADC Manufacturing: Practices, Challenges, And The Road Ahead6/15/2026
ADCs are advancing quickly, but manufacturing complexity is rising just as fast. Key challenges in scale-up, regulation, and costs are reshaping how the next generation of therapies will be delivered.
-
A Comprehensive Solution For Adventitious Agent Testing2/13/2026
Modern sequencing methods offer sensitive detection of adventitious and species‑specific viruses. Learn how targeted and non‑targeted NGS approaches improve confidence in cell bank characterization.
BIOSIMILAR APP NOTES & CASE STUDIES
- Application Of A Dual Spiking Strategy In Viral Clearance Studies
- Cell Culture Media Mixing In A Benchtop Single-Use Mixer
- A Sterilizing-Grade Membrane For Efficient Filtration Of Biologics
- Seamless Process Transfer Using An In Silico Bioreactor Scaling Tool
- Comparing Process Development Approaches For Recombinant Proteins
BIOSIMILAR DEVELOPMENT CONTENT COLLECTIONS
The debate over whether the biosimilar regulatory paradigm can shift away from comparative efficacy trials has intensified over the past few years. This collection of articles serves as a snapshot of the many different components of this ongoing discussion.
More Content CollectionsBIOSIMILAR DEVELOPMENT NEWS
- Waltz Health And Fresenius Kabi Expand Direct Access To Biosimilars Through Waltz Connect Platform
- Generic Medicines Manufacturers Ramp Up Patch Supply To Meet Demand
- Formycon And Zydus: FYB206 Becomes First Publicly Announced Keytruda Biosimilar Accepted For Review By FDA
- Xbrane Announces Full Recruitment Of Pivotal Clinical Trial For Xdivane
- Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- And Short-Acting G-CSF Options
- Thyme Companies Launches First New Venture, Thyme Therapeutics, To Build A More Sustainable, Lower-Cost Oncology Biosimilar Model
- LOTTE Biologics And Alvotech Announce US-Based Manufacturing Agreement To Increase Global Supply
- Kamada Announces Expansion Of Biosimilars Portfolio With The Launch Of Two Additional Products In Israel